125 related articles for article (PubMed ID: 27050374)
1. Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells.
Luo W; Song L; Chen XL; Zeng XF; Wu JZ; Zhu CR; Huang T; Tan XP; Lin XM; Yang Q; Wang JZ; Li XK; Wu XP
Oncotarget; 2016 May; 7(18):26709-23. PubMed ID: 27050374
[TBL] [Abstract][Full Text] [Related]
2. lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells.
Xiao Y; Jiao C; Lin Y; Chen M; Zhang J; Wang J; Zhang Z
DNA Cell Biol; 2017 Jan; 36(1):18-25. PubMed ID: 27854515
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
Illmer T; Schaich M; Platzbecker U; Freiberg-Richter J; Oelschlägel U; von Bonin M; Pursche S; Bergemann T; Ehninger G; Schleyer E
Leukemia; 2004 Mar; 18(3):401-8. PubMed ID: 14724652
[TBL] [Abstract][Full Text] [Related]
4. 7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyond MDR1 mechanism.
Rosa Fernandes L; Stern AC; Cavaglieri RC; Nogueira FC; Domont G; Palmisano G; Bydlowski SP
J Proteomics; 2017 Jan; 151():12-23. PubMed ID: 27343758
[TBL] [Abstract][Full Text] [Related]
5. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
6. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
Kuroda J; Yamamoto M; Nagoshi H; Kobayashi T; Sasaki N; Shimura Y; Horiike S; Kimura S; Yamauchi A; Hirashima M; Taniwaki M
Mol Cancer Res; 2010 Jul; 8(7):994-1001. PubMed ID: 20571063
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
[TBL] [Abstract][Full Text] [Related]
8. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia.
Wang JL; Liu HJ; Li F; Yang WY; Wang JM; Tan SF; Wang Q
Genet Mol Res; 2015 Nov; 14(4):14967-78. PubMed ID: 26634458
[TBL] [Abstract][Full Text] [Related]
11. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
12. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
[TBL] [Abstract][Full Text] [Related]
13. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
[TBL] [Abstract][Full Text] [Related]
14. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
16. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
17. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
18. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
Wu S; Zheng C; Chen S; Lin B; Chen Y; Zhou W; Li Z
Biochem Biophys Res Commun; 2015 Jan; 456(1):367-72. PubMed ID: 25475722
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]